SCHEMBL4173564

SCHEMBL4173564

Cn1c(=O)c(-c2ccccc2Cl)cc2cnc(NN3CC4CCCC4C3)nc21

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 2/20 0.64
LCK P06239 1/20 0.64
ABL1 P00519 2/20 0.58
FGFR1 P11362 9/20 0.55
RIPK2 O43353 2/20 0.54
ACVR1 Q04771 2/20 0.54
NOD2 Q9HC29 2/20 0.54
EGFR P00533 3/20 0.53
SRC P12931 3/20 0.53
WEE1 P30291 4/20 0.52
FGFR2 P21802 1/20 0.52
FGFR4 P22455 1/20 0.52
FGFR3 P22607 1/20 0.52
TNK2 Q07912 1/20 0.49
PAK1 Q13153 1/20 0.48
PDGFRB P09619 1/20 0.48
PDGFRA P16234 1/20 0.48
SIK1 P57059 1/20 0.48
SIK2 Q9H0K1 1/20 0.48
SIK3 Q9Y2K2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4183812 0.90 FGFR1 (0.68) MAPK14ABL1FGFR1EGFRSRC
SCHEMBL4186477 0.90 RIPK2 (0.54) MAPK14LCKABL1FGFR1RIPK2
SCHEMBL4181014 0.89 WEE1 (0.51) MAPK14LCKABL1FGFR1EGFR
SCHEMBL4183495 0.89 WEE1 (0.52) MAPK14LCKABL1FGFR1EGFR
SCHEMBL4186057 0.88 RIPK2 (0.56) MAPK14LCKABL1FGFR1RIPK2
SCHEMBL4187972 0.88 LCK (0.49) MAPK14LCKABL1FGFR1RIPK2
SCHEMBL13928692 0.87 WEE1 (0.51) MAPK14LCKABL1FGFR1EGFR
SCHEMBL4193028 0.86 PAK1 (0.54) MAPK14LCKABL1RIPK2ACVR1
SCHEMBL4192757 0.85 RIPK2 (0.53) MAPK14LCKABL1FGFR1RIPK2
SCHEMBL4186245 0.85 LCK (0.49) MAPK14LCKABL1FGFR1RIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090036472-A1 AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-02-05 US claimed
EP-1846403-A1 AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS Ranbaxy Laboratories Limited (IN) 2007-10-24 EP claimed
WO-2006082492-A1 AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-08-10 WO claimed
US-20090036472-A1 AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-02-05 US disclosed
US-20090036472-A1 AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-02-05 US disclosed
US-20090036472-A1 AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-02-05 US disclosed
EP-1846403-A1 AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS Ranbaxy Laboratories Limited (IN) 2007-10-24 EP disclosed
WO-2006082492-A1 AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036472-A1 AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS IL1B, TPMT, IL1R1 MAPK14 1323/4885LCK 944/4885ABL1 3754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.